Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Adriana C Rossi, MD, Tomer M Mark, MD, MSc, Kevin Wood, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Stanley Goldsmith, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1878.

https://doi.org/10.1182/blood.V122.21.1878.1878

Published: 2013

Journal Articles

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Angelique Boyer, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1954.

https://doi.org/10.1182/blood.V122.21.1954.1954

Published: 2013

Journal Articles

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Dennis Kwon, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2013) 122 (21): 1955.

https://doi.org/10.1182/blood.V122.21.1955.1955

Published: 2013

Journal Articles

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

Tomer M Mark, MD, MSc, John N. Allan, MD, Geoffrey Marano, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Linda Tegnestam, RN, Karen Pekle, NP, David Jayabalan, B.S.M.S, Morton Coleman, MD, Scott A Ely, MD, MPH, Ruben Niesvizky, MD

Blood (2013) 122 (21): 3216.

https://doi.org/10.1182/blood.V122.21.3216.3216

Published: 2013

Journal Articles

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Angelique Boyer, Adriana C Rossi, MD, Manan Shah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Linda Tegnestam, RN, Erlinda A Sacris, RN, June Greenberg, RN, Stephanie Speaker, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2012) 120 (21): 77.

https://doi.org/10.1182/blood.V120.21.77.77

Published: 2012

Journal Articles

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

Tomer M Mark, MD, MSc, Melissa Rodriguez, Manan Shah, Ryann Quinn, Jessica Campbell, Ramsey Abdullah, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 635.

https://doi.org/10.1182/blood.V118.21.635.635

Published: 2011

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Manan Shah, Melissa Rodriguez, Ryann Quinn, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Karen Pekle, NP, Patrice Mignott, RN, David Jayabalan, B.S.M.S, Scott A Ely, MD, MPH, Morton Coleman, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2011) 118 (21): 2937.

https://doi.org/10.1182/blood.V118.21.2937.2937

Published: 2011

Journal Articles

A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide

Tomer M Mark, MD, MSc, Adriana C Rossi, MD, Roger N Pearse, MD, PhD, Morton Coleman, MD, David Bernstein, Faiza Zafar, PA, Usama Gergis, MD, Tsiporah B. Shore, MD, Ruben Niesvizky, MD

Blood (2010) 116 (21): 2258.

https://doi.org/10.1182/blood.V116.21.2258.2258

Published: 2010

Journal Articles

Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma

Tomer M Mark, MD, MSc, Jennifer O'Loughlin, Morton Coleman, MD, David Jayabalan, B.S.M.S, Roger N Pearse, MD, PhD, Faiza Zafar, PA, Scott A Ely, Megan Manco, Patrice Mignott, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2010) 116 (21): 3050.

https://doi.org/10.1182/blood.V116.21.3050.3050

Published: 2010

Journal Articles

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Tomer Mark, MD, Morton Coleman, MD, David S Jayabalan, BSMS, Roger Pearse, MD/PhD, Faiza Zafar, PA, Scott Ely, MD, MPH, Megan C. Manco, Mary Crann, RN, John P. Leonard, MD, Selina Chen-Kiang, PhD, Ruben Niesvizky, MD

Blood (2009) 114 (22): 1861.

https://doi.org/10.1182/blood.V114.22.1861.1861

Published: 2009

Journal Articles

Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.

Jessica L. Stern, Brian Di Carlo, MD, Michael W. Schuster, MD, Tsiporah B. Shore, MD, John G. Harpel, MD,PhD, Roger Pearse, MD,PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 2953.

https://doi.org/10.1182/blood.V108.11.2953.2953

Published: 2006

Journal Articles

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Brian A. Di Carlo, MD, Jessica L. Stern, Michael Schuster, MD, Tsiporah Shore, MD, John Harpel, MD, PhD, Roger Pearse, MD, PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, MA, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 3538.

https://doi.org/10.1182/blood.V108.11.3538.3538

Published: 2006

NARROW

PET/CT Evaluation As a Prognostic Indicator In Relapsed Or Refractory Multiple Myeloma

Sequence Impact Of Pomalidomide and Carfilzomib On Treatment Response In Relapsed Multiple Myeloma

Clapd (Clarithromycin, Pomalidomide, Dexamethasone) Therapy In Relapsed Or Refractory Multiple Myeloma

Car-Bird [Carfilzomib, Clarithromycin(Biaxin (R) ), Lenalidomide/(Revlimid (R) ), Dexamethasone) For Newly-Diagnosed Multiple Myeloma

ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy in Newly Diagnosed Symptomatic Multiple Myeloma

A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization In Patients with Multiple Myeloma Treated with Lenalidomide

Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid ® ], Dexamethasone) Therapy for Upfront Use In Symptomatic Multiple Myeloma

T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy for Upfront Use in Symptomatic Multiple Myeloma.

Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma.

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only